retatrutide type 2 diabetes trial results 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ New Kind of Diabetes Drug

Mounjaro (tirzepatide) and Retatrutide (semaglutide) are both innovative medications that have shown remarkable success in helping individuals achieve their weight loss goals

Daniel Drucker et Joel Habener nauraient jamais imagin que leurs recherches sur le diabte de type 2 permettraient un jour de dvelopper des mdicaments qui aident les personnes obses perdre du poids

Prevalence of childhood and adult obesity in the United States, 2011-2012

The mechanism behind Retatrutide is what sets it apart

Read also: Hyperscaler AI Capex Tops $500 Billion Even as Burry Shorts the Chip Trade A Pfizer spokesperson declined to comment on the upfront fee, launch timeline, or pricing for ecnoglutide